No connection

Search Results

KRRO vs LFCR

KRRO
Korro Bio, Inc.
BEARISH
Price
$12.68
Market Cap
$182.9M
Sector
Healthcare
AI Confidence
85%
LFCR
Lifecore Biomedical, Inc.
BEARISH
Price
$4.75
Market Cap
$178.0M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
KRRO
--
LFCR
--
Forward P/E
KRRO
-1.67
LFCR
-5.72
P/B Ratio
KRRO
2.32
LFCR
-12.53
P/S Ratio
KRRO
28.61
LFCR
1.38
EV/EBITDA
KRRO
-1.82
LFCR
42.48

Profitability

Gross Margin
KRRO
0.0%
LFCR
31.37%
Operating Margin
KRRO
-1229.33%
LFCR
8.18%
Profit Margin
KRRO
0.0%
LFCR
-23.78%
ROE
KRRO
-110.7%
LFCR
--
ROA
KRRO
-32.14%
LFCR
--

Growth

Revenue Growth
KRRO
-43.1%
LFCR
--
Earnings Growth
KRRO
--
LFCR
--

Financial Health

Debt/Equity
KRRO
0.85
LFCR
4.15
Current Ratio
KRRO
6.9
LFCR
3.49
Quick Ratio
KRRO
6.38
LFCR
2.18

Dividends

Dividend Yield
KRRO
--
LFCR
--
Payout Ratio
KRRO
0.0%
LFCR
0.0%

AI Verdict

KRRO BEARISH

KRRO exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. While the company maintains a strong liquidity position with a current ratio of 6.90, this is offset by an extreme operating margin of -1229.33% and negative revenue growth of -43.10%. The stock is in a heavy technical downtrend, having lost over 70% of its value in the last six months. Despite a bullish analyst target of $20.00, the deterministic data suggests a high-risk speculative profile with no current path to profitability.

Strengths
Strong short-term liquidity (Current Ratio: 6.90)
Recent trend of beating EPS estimates (2/4 last quarters)
Significant upside gap to analyst target price ($20.00)
Risks
Extreme cash burn reflected in -1229.33% operating margin
Severe revenue contraction (-43.10% YoY)
Critical fundamental health (Piotroski F-Score: 1/9)
LFCR BEARISH

LFCR presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of valuation anchors like the Graham Number or Intrinsic Value. While the company shows strong short-term liquidity (Current Ratio 3.49) and positive Q/Q revenue growth, these are overshadowed by a critical negative book value (P/B -12.53) and excessive leverage (Debt/Equity 4.15). The technical trend is aggressively bearish (0/100), and the historical earnings track record is marked by extreme volatility and frequent misses.

Strengths
Strong short-term liquidity with a Current Ratio of 3.49
Positive Q/Q Revenue Growth of 25.92%
Positive Operating Margin of 8.18%
Risks
Negative Book Value (P/B -12.53) indicating significant equity erosion
High leverage with a Debt/Equity ratio of 4.15
Negative overall Profit Margin of -23.78%

Compare Another Pair

KRRO vs LFCR: Head-to-Head Comparison

This page compares Korro Bio, Inc. (KRRO) and Lifecore Biomedical, Inc. (LFCR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile